120
Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February 2007 & February 2011

Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Embed Size (px)

Citation preview

Page 1: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Osteomyelitis:Osteomyelitis:Pathophysiology &

Treatment Decisions

Clifford B. Jones, MD

Original Author: Clifford B. Jones, MD; March 2004 Revised February 2007 & February 2011

Page 2: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

“One Should Especially Avoid Such Cases if One has a Respectable

Excuse, for the Favorable Chances are Few and the Risks are Many….

Page 3: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

….Besides, if a Man does not Reduce the Fracture, He will be Thought Unskillful. If He does Reduce It, He will bring the Patient

Nearer to Death than Recovery.”

Hippocratic Writings, New York, Pelican Books, 1978

Page 4: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Fracture Management Goals

1. Osseous Union

2. Restore Limb Function

3. Avoid Complications

Page 5: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Osteomyelitis Results in:

1. Reduction in limb function

2. Psychological & Social dysfunction

3. Increased cost

Page 6: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Hansen’s 7 DsConcerning Prolonged Orthopaedic Problems

Despair

Divorce

Destitute

Depression

Delinquency

Default

DeathSigvard Ted Hansen, 1997

Page 7: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Introduction• 350,000 long bone fxs/yr

• Infection risk varies:– Type I open – 10/1,000 infections– Type III open – up to 25%

Page 8: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Gustilo Open Fx ClassJBJS, 72A: 299-303, 1990

2%

7%

7%10-50%25-50%

Page 9: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Open Fractures

Type II Type IIIA

Type IIIB Type IIIB

Page 10: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Negative Biology of Open Fx

Contamination

Crushing

Stripping

Devascularization

Comminution

Page 11: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Blood SupplyRhinelander, CORR, 1974

Page 12: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Blood SupplyRhinelander, CORR, 1974

Normal - endosteal/medullary 2/3-3/4

internal external

Fracture - periosteal/external majority

internal external

Periosteal Blood Supply Important

Page 13: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Centripetal FlowRhinelander, CORR, 1974

Page 14: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Initial Emergent Treatment

dT

Antibiotics, IV

Reduce

Stabilize

Cover wound

Page 15: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Why infection risk high?

Infection risk ≈ Fracture type (soft tissue)

Open fx = Contamination (70% cx +)

Open fx = Infected fx > 8 hours

Page 16: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Cost AnalysisInfection

– Increase cost 16-21%/pt

– Increase hosp stay 36-50%/pt

Total Cost $ 271 million/yr

Page 17: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Definition• Group of conditions• “…presence of bacteria & an

inflammatory response causing progressive destruction of bone.”– Fears, RL, et al, 1998

• “…suppurative process in bone caused by a pyogenic organism”

– Pelligrini, VD, et al, 1996

Page 18: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Why destruction of bone matrix?

Proteolytic enzymes

Hyperemia

Osteoclasts

Page 19: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Do Not Delay Tx & Dx

Page 20: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Classification• Waldvogel, 1971

– Classification based on pathogenesis

• May, 1989– 5 parts, post-traumatic tibial osteomyelitis

• Cierny & Mader, 1985– 4 factors affecting outcome

– Host, site, extent of necrosis, degree of impairment

Page 21: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

PathogenesisWaldvogel, 1971

1. Hematogenous

2. Contiguous focus of infection

3. Direct inoculation

Page 22: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

AnatomicClassification(Cierny-Mader)

1985

I:I: II:II:

III:III: IV:IV:

Page 23: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Classification Break-Down

I. MedullaryEndosteal nidus, min soft tissue involvement, ? Sinus tract

II. SuperficialSurface of bone, usu 2° to soft tissue defect

III. LocalizedLocalized sequestra, usu sinus tract, Usu stable s/p excision

IV. DiffusePermeative process, combination of I/II/III, Usu Unstable s/p excision

Page 24: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Physiologic Classification(Cierny-Mader, 1985)

A-Host: Good immune system & delivery

B-Host: Compromised hostBL: locally compromised

BS: systemically compromised

BC: combined

C-Host: Requires suppressive or no TxMinimal disabilityTx worse than dz, not a surgical candidate

Page 25: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Clinical Staging(Cierny-Mader, 1985)

Anatomic Type + Clinical StagePhysiologic ClassExample: IV BS tibial osteomyelitis = diffuse tibial lesion in a systemically compromised

host

Page 26: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Types of Pathophysiology

Acute/Hematogenous

Chronic/Nonhematogenous

Page 27: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Acute/Hematogenous

• Anatomy (Hobo)– Sharp twist in metaphyseal capillaries

• Stasis (Trueta)– Decreased flow in capillaries & veins

• Combination (Morrissy)– Trauma & Bacteria

Page 28: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Acute/HematogenousProgression of Dz

• Cell death 2° to bacterial exotoxins bacterial culture medium worsens condition

Vascularity, leukocytosis, edema Pressure w/in rigid osseous container Pain, swelling, erythemaPotential for septic arthritis (knee, hip, shoulder)

Page 29: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Chronic/Nonhematogenous

S. aureus ↑

Pseudomonas aureginosa ↑

Enterobacter

> 30% Polymicrobial> 30% Polymicrobial

Page 30: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Clinical Findings (varied)

Erythema

Swelling

Sinus Tract

Drainage

Limp

Fluctuence

NoneNone

PainPain

TendernessTenderness

FeverFever

HAHA

Nausea/VomitingNausea/Vomiting

Page 31: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Clinical Findings• Must have high index of suspicion

• Inappropriate use of Abx – obscure Sx

• Must obtain Dx quickly– If Tx started < 72°:

• Decrease incidence of chronic osteomyelitis

• Decrease destruction of bone

Page 32: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Laboratory DataAcute (Morrey, BF, OCNA, 1975)

WBC (25% of time)

– Abnormal differential, Left Shift (65%)

– Blood Cx – 50% positive

Chronic

– Mild anemia, WESR, C-reactive protein

– Possible leukocytosis with L shift

– Blood Cx – usually negative

Page 33: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Radiographs

Early – usu negative

Changes – delayed (10-21 days)

Page 34: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

RadiographsSoft Tissue

– Swelling, obscured soft tissue planes, haziness

Osseous– Hyperemia, demineralization

– Lysis (when > 40% resorbed)

– Periosteal reaction

– Sclerosis (late)

Page 35: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Radionucleotide Imaging

99M Tc

67Ga

111In WBC

Page 36: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

99M Tc

• Action

– binds to hydroxyapetite crystals

• Osteoblastic activity

– Demineralized bone

– Immature collagen

Page 37: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

99M Tc• 3 Phase Bone Scan

1. Radionucleotide angiogram

2. Immediate post injection blood pool

3. Three hour: soft tissue, urinary excretion

• Diagnosis– Cellulitis: Phases 1 &2, no change 3– Osteomyelitis: Phases 1 & 2, focal 3

• Results: 94% sensitivity, 95% specificity– Rosenthal 1992, Schauwecker 1992

Page 38: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Cellulitis

Page 39: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Osteomyelitis

Page 40: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

99M Tc: False Positive

DM foot d/o

Septic arthritis

Inflammatory bone dz

Adjacent to pressure sores

Page 41: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

99M Tc

4 Phase Bone Scan• New development

• Action:

– Mature bone: uptake stops at 4 hr

– Immature woven bone: cont’d uptake at 24 hr

• Problem: needs f/u imaging at 24 hr (compliance)• Gupta 1988, Israel 1987, Schauwecker 1992

Page 42: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

67Ga

• Exudation of in vivo labeled serum protein– Transferrin, haptoglobin, albumin

• Results– 81% sensitivity, 69% specificity– Schauwecker, 1992

• Combination with Tc sensitivity, but specificity

Page 43: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

111In WBC

• Used in combination (Seabold, 1989)– In/Tc: 88% accurate– Ga/Tc: 39% accurate

• Preparation problem rad dose to spleen, 18-24hr delay

• Spine (Whalen, Spine 1991)– 83% false negative use MRI

Page 44: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

MRINo radiation

Good soft tissue imaging

Imaging:– T1 Dark– T2 Bright/Mixed

Page 45: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

T1 bright T2 dark

Page 46: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

T1 bright T2 dark

Page 47: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

MRI• Acute:

marrow fat granulation tissue H2O

• Chronic: thickened cortex– Low signal on all scans

• Cellulitis: no marrow changes

Page 48: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

MRI ResultsSchauwecker, 1992

• Sensitivity 92-100%

• Specificity 89-100%

• Excellent for Spine (Modic, RCNA, 1986)– Sens 96%, Spec 92%, Accuracy 94%

• Soft tissue extension

• Sinus tract formation– Bright Tx from skin to bone

Page 49: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

CT ImagingImage cortical and cancellous bone

Evaluate osseous adequacy of debridement

Page 50: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Aspiration BiopsyAcute

– Good, only 10-15% false negative

Chronic– Sinus tract cx: 76% sens, 80% spec– 70% with S aureus & Enterococcus– 30% Pseudomonas– Does not determine correct Abx

Page 51: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Acute/Hematogenous

Page 52: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Changing Bacterial Pathogens

Page 53: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Resistant Bacterium - ESKAPE

E Enterococcus faecuim

S Staphlococcus aureus

K Klebsiella pneumoniae

A Acinobacter baumannii

P Pseudomonas aeruginosa

E Enterobacter aerogenes

Page 54: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

MSSA & MRSA

• MSSA Change to β lactam

• MRSA Treat ≤ MIC

Page 55: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Gram Negative Rods - SPICE

S Serratia

P Pseudomonas

I Indole positive

C Citrobacter

E Enterobacter

Page 56: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Gram Negative

Rods

Page 57: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Proionibacterium acnes• Axillary bacteria (sebaceous glands)

• Treated with:– 1st: PCN or vanco– 2nd: Macrolides & Fluoroquinolones

• Long incubation time

• Call lab – culture 2 wks, gram positive rods

• Especially important for shoulder:– Nonunions– Infections

Page 58: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Multilocus Polymerase Chain reaction & Electrospray Ionization/Mass Spectrometry

• Bacterial or fungal DNA is amplified by polymerase chain reaction and introduced into a mass spectroscopy by electrospray ionization

• The amplification procedure uses 16 S primers, and the primers can be varied to detect fungi and antibiotic resistance genes (eg, mec A).

Page 59: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Multilocus Polymerase Chain reaction & Electrospray Ionization/Mass Spectrometry

• Although culturing bacteria takes days, amplifying DNA takes hours

• Accurate, rapid point-of-care devices would be ideal for clinical use

Page 60: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Treatment Preventation

• Antibiotics – correct organism

• Debridement – until viable tissue obtained

• Irrigation

• Wound care/coverage

• Osseous & soft tissue stability– Fx stability– Dead space management

Page 61: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

New Oral Agents: MRSA

Zyvox/linazid po/iv ↓ plts

Synercid iv

Infectious Disease Consult

Page 62: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Stability Oxymoron

Hardware increased ↑ bacterial growth

&

Fracture stability (hardware) ↓ bacterial growth

Page 63: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Glycocalyx = “slime”

Remove hardware, exchange for new once infection under controlRemove hardware, exchange for new once infection under control

Page 64: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Dead Space Control

Page 65: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Abx IMN Materials & Methods

Research: Retrospective Review

Time: 3 year period, 2 year F/U

Location: Level 1 Trauma Center

Page 66: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

PatientsAge: 37 (range 18-67)

Femurs (n=4)

Closed n=2

Open n=2

Tibia (n=28)

Closed n=2

Open n=26

II: 4/26

IIIA: 12/26

IIIB: 10/28

10/28 open tibial fx with rotational or FTT for coverage

Page 67: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Antibiotic NailInserted Avg. 3 mo. (range 2 day – 23 mo.)

2 bags PMMA

2.O g Vancomycin

2.4 g Tobramycin

32 Fr Chest Tube

3.2 mm Guide Wire

Page 68: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Incise & Debride WoundI&D Wound

I&D Canal

Reamers, Vent Hole

Page 69: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Presentation

44 M44 M

4 bacterium4 bacterium

CoccidiomycosisCoccidiomycosis

2 prior known “flare ups”2 prior known “flare ups”

Page 70: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Antibiotic IMN

32 Fr Chest Tube2 bags PMMA2.0 Vancomycin2.4 Tobramycin

Insert under pressure into chest tube while still “wet”

Insert 3.2 mm ball tip guide rod

Remove plastic before PMMA too hot and melting plastic chest tube

Page 71: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Insert Abx IMN

Page 72: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Wait until IMN Insertion

Wound Healed

Labs Improved

Anabolic Host

Usually 4-8 wks

(Average 4-8 wks)(Average 4-8 wks)

Page 73: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Example

Page 74: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February
Page 75: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Infected Tibial Nonunion

• 32 M

• 2 ppd smoker

• MCA 18 mo, 2 prior surgeries

• Draining wound

• “No one to take care of him”– Translation No money

Page 76: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Presentation

Page 77: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Options

• Type IV BC

• Unstable with Osteo• Smoker, malnutrition• Local open wound

• Nothing• Revise with plate• Revise with nail• Revise with ex fix• Revise with Ilizarov• Amputation

Length +/-

Page 78: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Debridement of Skin & BoneDebridement of Skin & Bone

Page 79: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Dead Space Management

Page 80: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Stabilize NonunionStabilize Nonunion

Page 81: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Coverage of Wound

Page 82: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Lengthening Leg

Page 83: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Noncompliance - NonunionNoncompliance - Nonunion

Page 84: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Final – Healed with GraftingFinal – Healed with Grafting

Page 85: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Infected Tibial Nonunion

• 38 yo M

• Snuff tobacco

• 1 pint vodka/day

• 6 mo MCA with IIIB open tibia

Type I BS

Page 86: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Presentation

Page 87: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Initial Post opInitial Post op

Page 88: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

3 mo

Page 89: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Exchange IMN at 4 ½ moExchange IMN at 4 ½ mo

Page 90: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Final at 18 moFinal at 18 mo

Page 91: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Example• 54 yo Male• Post-operative Pseudomonas osteomyelitis• Refractory to HW removal & Ancef• Healthy, non-smoking• Cierny III A Host

Photos from M Swiontkowski

Page 92: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Example 1

•Dead Space

•Calcaneal defect

Page 93: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Example 1• Debridement of all non-viable bone with

laser doppler

• Defect filled with antibiotic PMMA

• 6 wks antibiotics

Page 94: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Example 1, at 6 wks

• Removal Abx beads• Bone grafting• Lateral arm flap• Infection eradication

Page 95: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Example• 47 yo Male, smoker• Presentation 2 months s/p ORIF closed proximal

tibia fx• Draining wound• Exposed HW• Cierny III BC Host

• Photos from M Swiontkowski

Page 96: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Example

• Debridement

• HW remains

• Abx beads

Exposed plate

Page 97: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Example • Gastrocnemeus flap, STSG

Page 98: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Example • At 6 weeks

• Remove Abx beads

• Bone grafting

• Healed wound and fracture

Page 99: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Example• At 5 yo, tibial osteomyelitis• Partially treated• At 62 yo, presentation to MD• Chronic draining tibial osteomyelitis• Cierny III BC Host

• Photos from M Swiontkowski

Page 100: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Example•Sinus tracts

•Chronic skin changes

Page 101: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Example•I&D to normal bleeding bone with laser doppler

•Bx – negative for cancer

Page 102: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Example

• Abx beads

• Latissimus Flap

• STSG

Page 103: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Example• Removal Abx beads at 6 wks

• No bone graft – low demand patient

• Dz free at 8 years (70 yo)

Page 104: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February
Page 105: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February
Page 106: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

The Fate of Patients with a “Surprise” Positive Culture

After Nonunion Surgery

Olszewski D, Stucken C, Tornetta III P, Ricci W, Struebel P, Jones C, Sietsema D

Page 107: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Results• 460 patients

• Two cohort groups

– 98 cultures (21%) “surprise” positive

– 362 cultures (79%) negative

Page 108: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

BacteriaType of Bacteria Number

Coagulase-negative Staphylococcus 45

Methicillin-resistant S. Aureus 12

Pseudomonas 8

Proprionibacterium 8

Methicillin-sensitive S. Aureus 7

Bacillus 4

Peptostreptococcus 3

Staph species unspecified 3

Enterococcus 2

Strep viridans 2

Clostridium 2

E. coli, Staph epidermidis, Beta hemolytic strep,

Serratia, Candida and Aspergillus 1

Page 109: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Positive Cultures

• 98 with positive cultures

– 90 treated with antibiotics

• 6 – 8 week duration

• Culture specific

– 8 patients not treated

• “Presumed contaminant”

Page 110: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Union After Index

• Culture (+) = 66 / 90 (73%)

• Culture (-) = 347 / 362 (96%)

• P < 0.0001

Page 111: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Infection After Index

• Culture (+) = 11 / 90 (12%)

• Culture (-) = 15 / 362 (4%)

• P < 0.0001

Page 112: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Final Outcome• Culture (+) = 86 / 90 (95.5%)

– 24 Additional procedures – 9 / 13 Debridement only– 4 / 13 with 1 additional procedure– 4 / 90 (4.5%) infected nonunion– 2 BKA

• Culture (-) = 362 / 362 (100%)– 15 Additional procedures

• P < 0.0001

Page 113: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

“Presumed Contaminants”• 8 “surprise” cultures not treated with antibiotics

– Deemed “contaminants”– 5 Healed– 3 Nonunions

• 1 Amputation

• 1 Infected nonunion

• 1 Non-infected nonunion

Page 114: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

  Culture Positive Culture Negative

Healed 73% 95.8%

Infected Nonunion

13% 4%

Additional Procedures

27% 4%

Union at final follow-up

93% 100%

All Patients

Page 115: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Summary

• 21% of 460 “at risk” nonunions had surprise positive culture

• Staph species

• 90 of 98 treated with antibiotics

Page 116: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Summary• Culture positive

–73% Index

–93% Final• Culture negative

–95.5% Index

–100% Final

Page 117: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

“Surprise” cultures• Revision shoulder arthroplasty

– 17 to 29% “surprise” positives– 13 to 25% require re-revision

• Revision hip arthroplasty – 11% “surprise” positives– 13% require re-revision

1. Kelly II JD, Hobgood ER. Positive culture rate in revision shoulder arthroplasty. Clin Orthop Relat Res. 2009;467:2243-48.2. Topolski MS, Chin PY, Sperling JW, Cofield RH. Revision shoulder arthroplasty with positive intraoperative cultures: the value of preoperative

studies and intraoperative histology. J Shoulder Elbow Surg. 2006;15:402-406.3. Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty: a study of the treatment of one hundred and six infections. J Bone

Joint Surg Am. 1996;78:512-523.

Page 118: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Conclusions• 21% “surprise” positive cultures

• 74% heal after initial index procedure

• 26% required additional procedures

Page 119: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Recommendations

• Counsel patients

• Treat all positive cultures

• Potentially offer two-stage procedures– Unknown efficacy– 79% would be unnecessary

Page 120: Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February

Conclusion

Prevention

Early Dx

Early Tx

Stabilize

Convert to Union ASAP

Return to General/Principles

Index

E-mail OTA about

Questions/Comments

If you would like to volunteer as an author for the Resident Slide Project or recommend updates to any of the following slides, please send an e-mail to [email protected]